Anandamide receptors

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 66, Issue 2-3, 2002, Pages 377-391

  Di Marzo, V ^a,b   De Petrocellis, L ^c   Fezza, F ^b   Ligresti, A ^b   Bisogno, T ^b  

^a Endocannabinoid Research Group   (Italy)

^b Istituto di Chimica Biomdecolare   (Italy)

^c CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANANDAMIDE RECEPTOR; CALCIUM CHANNEL L TYPE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR; CAPSAICIN; CATION CHANNEL; G PROTEIN COUPLED RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; IONOTROPIC RECEPTOR; POTASSIUM CHANNEL; PROTON; UNCLASSIFIED DRUG; VANILLOID RECEPTOR; AMIDE; ANANDAMIDE; ARACHIDONIC ACID DERIVATIVE; DRUG RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

APOPTOSIS; BRAIN; BRONCHOSPASM; CANCER INHIBITION; CHANNEL GATING; HIPPOCAMPUS; ION CURRENT; MOUSE; NOCICEPTION; NONHUMAN; PRIORITY JOURNAL; RECEPTOR UPREGULATION; REVIEW; SMOOTH MUSCLE TONE; VASCULAR ENDOTHELIUM; VASODILATATION; ANIMAL; CHEMISTRY; METABOLISM;

ANIMALS; ARACHIDONIC ACIDS; BRAIN; CALCIUM CHANNELS, L-TYPE; ENDOTHELIUM, VASCULAR; POLYUNSATURATED ALKAMIDES; POTASSIUM CHANNELS; RECEPTORS, CANNABINOID; RECEPTORS, DRUG; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 0036019422     PISSN: 09523278     EISSN: None     Source Type: Journal    
DOI: 10.1054/plef.2001.0349     Document Type: Article

References (115)

1. Anandamide, an endogenous cannabinomimetic eicosanoid: 'Killing two birds with one stone'
2. 'Endocannabinoids' and other fatty acid derivatives with cannabimimetic properties: Biochemistry and possible physiopathological relevance
3. Isolation and structure of a brain constituent that binds to the cannabinoid receptor
4. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors
5. 2-Arachidonoylglycerol: A possible endogenous cannabinoid receptor ligand in brain
6. 2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor
7. Pharmacology of cannabinoid receptor ligands
8. Molecular probes for the cannabinoid receptors
9. Cannabimimetic fatty acid derivatives: The anandamide family and other endocannabinoids
10. Endocannabinoids Part I: Molecular basis of endocannabinoid formation, action and inactivation and development of selective inhibitors
11. Levels, metabolism and pharmacological activity of anandamide in CB(1) cannabinoid receptor knockout mice: Evidence for non-CB(1), non-CB(2) receptor-mediated actions of anandamide in mouse brain
12. Assessment of anandamide interaction with the cannabinoid brain receptor: SR141716A antagonism studies in mice and autoradiographic analysis of receptor binding in rat brain
13. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice
14. Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice
15. Influence of phenylmethylsulfonyl fluoride on anandamide brain levels and pharmacological effects
16. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase
17. Intrastriatal injection of cannabinoid receptor agonists induced turning behavior in mice
18. Antinociceptive activity of the endogenous fatty acid amide, palmitylethanolamide
19. Cardiovascular effects of 2-arachidonoyl glycerol in anesthetized mice
20. Inhibition of intestinal motility by anandamide, an endogenous cannabinoid
21. Anandamide, an endogenous cannabinoid receptor ligand, also interacts with 5-hydroxytryptamine (5-HT) receptor
22. Anandamides inhibit binding to the muscarinic acetylcholine receptor
23. Interaction of anandamide with the M(1) and M(4) muscarinic acetylcholine receptors
24. 1 cannabinoid receptors in cultured astrocytes
25. Evidence for a new G-protein-coupled cannabinoid receptor in mouse brain
26. 35S] GTPγS binding in the CB1 knockout mice
27. Novel cannabinoid-sensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus
28. Mesenteric vasodilation mediated by endothelial anandamide receptors
29. 2 receptors
30. 1 cannabinoid receptor
31. Neurobehavioral activity in mice of N-vanillyl-arachidonyl-amide
32. Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation
33. Vasodilator activity of arvanil (N-arachidonoyl-vanillyl-amide), a novel "hybrid" activator nof vanilloid and cannabinoid receptors
34. Hypolocomotor effects in rats of capsaicin and two long chain capsaicin homologues
35. Highly selective CB(1) cannabinoid receptor ligands and novel CB(1)/VR(1) vanilloid receptor 'hybrid' ligands
36. A structure/activity relationship study on arvanil, an endocannabinoid and vanilloid hybrid
37. 2+ channel current
38. Isolation, identification and synthesis of an endogenous arachidonic amide that inhibits calcium channel antagonist 1,4-dihydropyridine binding
39. 2+ channel
40. Arachidonylethanolamide (anandamide) binds with low affinity to dihydropyridine binding sites in brain membranes
41. Inhibition by anandamide of gap junctions and intercellular calcium signalling in striatal astrocytes
42. Arachidonic acid amide inhibitors of gap junction cell-cell communication
43. Dual effects of anandamide on NMDA receptor-mediated responses and neurotransmission
44. + channels
45. The endocannabinoid anandamide is a direct and selective blocker of the background K(+) channel TASK-1
46. Influence of cannabinoids on the delayed rectifier in freshly dissociated smooth muscle cells of the rat aorta
47. The capsaicin receptor: A heat-activatedion channel in the pain pathway
48. Capsaicin: Cellular targets, mechanisms of action, and selectivity for thin sensory neurons
49. Resiniferatoxin and its analogs provide novel insights into the pharmacology of the vanilloid (capsaicin) receptor
50. Immunocytochemical localization of the vanilloid receptor 1 (VR1): Relationship to neuropeptides, the P2X3, purinoceptor and IB4 binding sites
51. The cloned capsaicin receptor integrates multiple pain-producing stimuli
52. Vanilloid receptor-1 is essential for inflammatory thermal hyperalgesia
53. Impaired nociception and pain sensation in mice lacking the capsaicin receptor
54. Neuropharmacological mechanisms of capsaicin and related substances
55. Distribution of mRNA for vanilloid receptor subtype 1 (VR1), and VR1-like immunoreactivity, in the central nervous system of the rat and human
56. Cloning and functional expression of a human orthologue of rat vanilloid receptor - 1
57. The tissue distribution and functional characterization of human VR1
58. A capsaicin-receptor antagonist, capsazepine, reduces inflammation-induced hyperalgesic responses in the rat: Evidence for an endogenous capsaicin-like substance
59. New perspectives on enigmatic vanilloid receptors
60. Interactions between synthetic vanilloids and the endogenous cannabinoid system
61. Anandamide transport inhibition by the vanilloid agonist olvanil
62. Antihyperalgesic effects of spinal cannabinoids
63. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide
64. The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1)
65. Anandamide and the question of its functional role for activation of capsaicin receptors
66. Regional differences in anandamide- and, methanandamide- induced membrane potential changes in rat mesenteric arteries
67. Anandamide induces cardiovascular and respiratory reflexes via vasosensory nerves in the anaesthetized rat
68. The endogenous cannabinoid agonist, anandamide stimulates sensory nerves in guinea-pig airways
69. The vanilloid receptor (VR1)-mediated effects of anandamide are potently enhanced by the cAMP-dependent protein kinase
70. A possible role of lipoxygenase in the activation of vanilloid receptors by anandamide in the guinea-pig bronchus
71. Bidirectional control of airway responsiveness by endogenous cannabinoids
72. Structure-activity relationship for the endogenous cannabinoid, anandamide, and certain of its analogues at vanilloid receptors in transfected cells and vas deferens
73. Differential effects of anandamide on acetylcholine release in the guinea-pig ileum mediated via vanilloid and non-CB1 cannabinoid receptors
74. Anandamide excites central terminals of dorsal root ganglion neurons via vanilloid receptor-1 activation
75. Anandamide activates peripheral nociceptors in normal and arthritic rat knee joints
76. Spinal anandamide inhibits nociceptive transmission via cannabinoid receptor activation in vivo
77. Cannabinoid CB(1) receptor expression in rat spinal cord
78. Cannabinoid 1 receptors are expressed in nociceptive primary sensory neurons
79. Presynaptic inhibition caused by retrograde signal from metabotropic glutamate to cannabinoid receptors
80. Actions of putative endogenous cannabinoids on synaptic transmission in the rat hippocampal slice
81. Anandamide induces apoptosis in human cells via vanilloid receptors. Evidence for a protective role of cannabinoid receptors
82. Inhibition of rat C6 glioma cell proliferation by endogenous and synthetic cannabinoids. Relative involvement of cannabinoid and vanilloid receptors
83. Mechanisms of anandamide-induced vasorelaxation in rat isolated coronary arteries
84. Effect of vanilloid drugs on gastrointestinal transit in mice
85. Pharmacology of cannabinoid CB1 and CB2 receptors
86. The activity of anandamide at vanilloid VR1 receptors requires facilitated transport across the cell membrane and is limited by intracellular metabolism
87. Capsaicin binds to the intracellular domain of the capsaicin-activated ion channel
88. Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: Inhibitors of anandamide uptake with negligible capsaicin-like activity
89. The anandamide transport inhibitor AM404 activates vanilloid receptors
90. Cannabinoid activation of recombinant and endogenous vanilloid receptors
91. Induction of vanilloid receptor channel activity by protein kinase C
92. Protein kinase C activation potentiates gating of the vanilloid receptor VR1 by capsaicin, protons, heat and anandamide
93. The palmitoylethanolamide and oleamide enigmas: Are these two fatty acid amides cannabimimetic?
94. Palmitoylethanolamide enhances anandamide stimulation of human vanilloid VR1 receptors
95. Anandamide activates vanilloid receptor 1 (VR1) at acidic pH in dorsal root ganglia neurons and cells ectopically expressing VR1
96. Temperature-dependent activation of recombinant rat vanilloid VR1 receptors expressed in HEK293 cells by capsaicin and anandamide
97. Anandamide: Some like it hot
98. Protein kinase C disrupts cannabinoid actions by phosphorylation of the CB1 cannabinoid receptor
99. Biosynthesis of an endogenous cannabinoid precursor in neurons and its control by calcium and cAMP
100. Formation and inactivation of endogenous cannabinoid anandamide in central neurons
101. Direct activation of capsaicin receptors by products of lipoxygenases: Endogenous capsaicin-like substances
102. Biosynthesis, uptake, and degradation of anandamide and palmitoylethanolamide in leukocytes
103. Glutamate stimulates the formation of N-acylphosphatidylethanolamine and N-acylethanolamine in cortical neurons in culture
104. Pathways and mechanisms of N-acylethanolamine biosynthesis: Can anandamide be generated selectively?
105. N-acylphosphatidylethanolamine-hydrolysing phospholipase D lacks the ability to transphosphatidylate
106. Marked activation of the N-acylphosphatidylethanolamine-hydrolyzing phosphodiesterase by divalent cations
107. Anandamide, an endogenous cannabinomimetic substance, modulates rat brain protein kinase C in vitro
108. Anandamide stimulates phospholipase D activity in PC12 cells but not in NIH 3T3 fibroblasts
109. The endogenous cannabinoid anandamide is a lipid messenger activating cell growth via a cannabinoid receptor-independent pathway in hematopoietic cell lines
110. Involvement of the cAMP/protein kinase A pathway and of mitogen-activated protein kinase in the anti-proliferative effects of anandamide in human breast cancer cells
111. Cannabinoids activate p38 mitogen-activated protein kinases through CB1 receptors in hippocampus
112. R(+)-methanandamide induces cyclooxygenase-2 expression in human neuroglioma cells via a non-cannabinoid receptor-mediated mechanism
113. Cannabinoid-receptor-independent cell signalling by N-acylethanolamines
114. Molecular targets for cannabidiol and its synthetic analogues: Effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide